Valence 로고
인기
로그인
Loading data for BIVI — first visit, this takes a few seconds.

관심목록에 추가

BioVie Inc.

NasdaqCM: BIVI · 실시간 가격 · USD
0.96
-0.21 (-17.95%)
종가 기준: Aug 18, 2026, 3:59 PM

BioVie Inc. (BIVI) Stock Price, Analysis & Data

-17.95%
매수호가0.81
시가총액7.27M
매출 (ttm)n/a
순이익 (ttm)-22.03M
베타n/a
EPS (ttm)-3.05
P/E (ttm)n/a
선행 P/E-1.69
P/B (ttm)0.71
P/S (ttm)n/a
Earnings DateAug 24, 2026
매도호가1.22
거래량3,138,118
평균 거래량 (20일)2,668,132
시가1.13
전일 종가1.17
일중 범위0.95 - 1.14
52주 범위0.82 - 3.79
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

BIVI 소개

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally adminis...

[더 보기]
산업 Biotechnology
섹터 Healthcare
IPO 일자 Sep 18, 2020
직원 수 n/a
상장 거래소 NasdaqCM
티커 BIVI
웹사이트 https://bioviepharma.com
전체 기업 정보

재무 실적

2025년 BioVie의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -17.54M로, -45.39% 감소했습니다.

재무제표

어닝 서프라이즈

BioVie가 Nov 10, 2025에 분기 실적을 발표했습니다:
  • 매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
  • EPS -0.98 예상치 하회 -0.19, 및 95.10% 전년 대비 성장.

    • 다음 실적 발표

    BioVie Inc.의 실적 발표 예정일은 Aug 24, 2026, 장 마감 후입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    1주 전 · Proactive

    Parkinson's drug developers are betting big on inflammation

    For years, the hunt for a Parkinson's disease-modifying drug came down to one protein: alpha-synuclein. Clear it out, the thinking went, and you slow the disease. That bet hasn't paid off yet. Now a g...

    news image

    1주 전 · Clinical Trials Arena

    BioVie stock sinks on Phase IIb Parkinson’s trial data

    BioVie used an endpoint called EPNIC-15, which is not well known and only appears to be referenced in papers by the company itself.

    news image

    1주 전 · Proactive

    BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim

    BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its drug candidate bezisterim met the prespecified endpoints of a Phase 2 trial in early-stage Parkinson's disease, with patients showing improvements in bl...

    news image

    1주 전 · Proactive

    BioVie reports positive phase 2 Parkinson's results, eyes pivotal Phase 3 trial

    BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) CEO Cuong Do joined Steve Darling from Proactive to discuss positive results from the company's 60-patient Phase 2 clinical trial of bezisterim in Parkinson's di...

    news image

    2개월 전 · Proactive

    BioVie: Long COVID trial fully enrolled – ICYMI

    BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week announced that its Phase 2 long COVID trial evaluating bezisterim has achieved full enrollment, marking an important milestone for the biotechn...

    2 페이지 중 1